Cancer immunotherapeutics meeting Journal Article
| Author: | Slovin, S. F. |
| Article Title: | Cancer immunotherapeutics meeting |
| Abstract: | The annual meeting of Cancer Immunotherapeutics held in Boston integrated a multi-disciplinary audience of scientists from academia and biotech companies, as well as venture capitalists, in an attempt to bring to the fore-front the most thought-provoking approaches toward cancer immunotherapy as well as innovations in biotechnologies. The major focus of the meeting was to bring together investigators to discuss technologies that can enhance immune responsiveness. Major themes included the enhancement of T-cell recognition and killing by the addition of cytokines or through novel inhibitors of in vitro cell signalling factors. Many of the presentations were based on studies that may provide the groundwork for translation into the clinic. Another goal of this meeting was to foster collaborations among investigators to facilitate and extend current research objectives. © 2004 Ashley Publications Ltd. |
| Keywords: | unclassified drug; clinical trial; bevacizumab; nonhuman; conference paper; cancer adjuvant therapy; rituximab; antineoplastic agent; neoplasms; lymphocyte proliferation; t lymphocyte; animals; bcg vaccine; canvaxin; cytotoxic t lymphocyte antigen 4 antibody; unindexed drug; cancer immunotherapy; melanoma; multiple myeloma; dendritic cell; nausea; myalgia; epidermal growth factor receptor 2; granulocyte macrophage colony stimulating factor; antineoplastic activity; in vitro study; cetuximab; telomerase; kidney carcinoma; monoclonal antibody; arthralgia; chill; digestive system cancer; drug fever; fever; prostate cancer; pruritus; drug cost; cancer genetics; cytokine; immune response; immunotherapy; cancer vaccine; molecular recognition; psa; erythema; immunological adjuvant; flu like syndrome; headache; adenovirus vector; antibodies; gonadorelin agonist; provenge; tumor cell vaccine; trastuzumab; adjuvants, immunologic; chronic lymphatic leukemia; humoral immunity; genetic screening; oligonucleotide; adoptive immunotherapy; antigen presenting cell; macrogol; alemtuzumab; liposome; polyglactin; drug delivery system; cell killing; injection site; vaccines; skin ulcer; drug formulation; keyhole limpet hemocyanin; toll-like receptors; skin inflammation; bystander effect; t-cells; gm-csf; adjuvant; vitiligo; indoleamine 2,3 dioxygenase inhibitor; active immunization; passive immunization; herpes simplex vaccine; bacterial antigen; acid phosphatase prostate isoenzyme; neutrophilia; g vax; aluminum hydroxide; injection pain; humans; human; retina degeneration; collagen antibody; lipid a derivative; biotechnological production |
| Journal Title: | Expert Opinion on Investigational Drugs |
| Volume: | 13 |
| Issue: | 12 |
| ISSN: | 1354-3784 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2004-12-01 |
| Start Page: | 1645 |
| End Page: | 1650 |
| Language: | English |
| DOI: | 10.1517/13543784.13.12.1645 |
| PROVIDER: | scopus |
| PUBMED: | 15566321 |
| DOI/URL: | |
| Notes: | Expert Opin. Invest. Drugs -- Export Date: 16 June 2014 -- CODEN: EOIDE -- Source: Scopus |
